M. Margaret Kemeny, MD

Schering-Plough Research Institute, Gene Therapy of Primary and Metastatic Malignant\r\nTumors of the Liver Using SCH 58500 (rAd/p53) Via Hepatic Artery Infusion: A\r\nPhase I Study

\r\n

A Two-Stage Phase II Safety and Efficacy\r\n Study of Intradose (Cisplatin/Epinephrine) Injectable Gel Administered to Patients\r\n with Unresectable Intrahepatic Colorectal Metastases

\r\n

A Two-Stage Phase II Safety and Efficacy\r\n Study of IntraDose (Displatin/Epinephrine) Injectable Gel Administered to Patients\r\n with Unresectable Primary Hepatocellular Carcinoma

\r\n

The Long Island Breast Cancer Study Project

\r\n

CALGB protocol 9481: Phase III Study of Hepatic Artery FUDR, Leucovorin (LV)\r\n and Dexamethasone versus systemic 5-Fu and LV as treatment for hepatic metastases\r\n from colorectal cancer

\r\n

ECOG Protocol 3292: Biologic correlates to response and survival in colon\r\n cancer

\r\n

NIH study: Genetics of Breast Cancer Among Women of Jewish Ancestry

\r\n

CALGB protocol 9670: Barriers to Participation of Older Women with Breast\r\n Cancer in Clinical Trials: A Pilot Study

\r\n

Intergroup protocol 9288, SWOG 8990: Combined modality treatment of hepatic\r\n metastases from colorectal cancer

\r\n

Intergroup protocol ECOG 1292, SWOG 9250, CALGB 9395: Phase III Intergroup\r\n prospectively randomiized trial of perioperative 5FU after curative resection\r\n followed by 5 FU/levamisole for patients with colon cancer

\r\n